Tysabri Progressive Multifocal Leukoencephalopathy Attorney: New Jersey Legal Help for PML Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specialized Legal Needs

For decades, the public health landscape has been shaped by broad educational initiatives aimed at improving general wellness and disease prevention. These efforts have successfully raised awareness about lifestyle factors, routine screenings, and the importance of informed medical decision-making. Within this legacy, the focus has largely remained on common conditions and widely understood risk factors, providing a foundation for individuals to engage proactively with their healthcare providers. As this general health framework evolved, it increasingly encountered specialized areas where patient outcomes depend on nuanced understanding of specific therapies and their potential complications. One such area involves the use of biologic medications for chronic autoimmune conditions. While these treatments offer significant benefits, they also introduce considerations that extend beyond typical health maintenance. For patients and their families, navigating these complexities often requires not only medical guidance but also legal awareness when adverse events occur. This is particularly relevant when a prescribed therapy is linked to serious neurological risks. In such cases, the transition from general health information to a focused concern about occupational or environmental exposure becomes critical. For individuals who have received treatments like Tysabri and subsequently developed conditions such as progressive multifocal leukoencephalopathy, the need for specialized legal counsel arises. Understanding this risk profile is essential for those seeking representation, especially in jurisdictions like New Jersey where pharmaceutical liability cases require careful navigation of both medical and legal standards.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The United States Food and Drug Administration (FDA) has mandated a boxed warning for Tysabri, the strongest safety alert, to communicate this risk. The boxed warning explicitly states that Tysabri increases the risk of PML and that risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Evidence and Risk Factors for PML in Tysabri Patients

PML is a demyelinating disease of the central nervous system. A large retrospective national cohort study of PML patients observed between 1987 and 2024, including 456 cases with definite or clinico-radiological diagnosis, described the changing clinical and laboratory characteristics of the disease (https://pubmed.ncbi.nlm.nih.gov/40922664/). The study highlights that PML affects immunocompromised individuals and that its presentation and outcomes vary by underlying condition. In Tysabri-treated patients, PML typically presents with progressive neurological deficits such as cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis is confirmed by brain MRI showing demyelinating lesions and by detection of JCV DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of lymphocytes into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination. The risk is highest in patients who are anti-JCV antibody positive, have received Tysabri for more than two years, or have a history of immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Adverse event reports from the FDA Adverse Event Reporting System (FAERS) list fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased among the most frequently reported events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically isolate PML, they reflect the neurological and functional impairments that may be early signs of PML or other complications.

Legal Considerations for Tysabri-Related PML in New Jersey

From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central concern. The boxed warning and the TOUCH program are designed to mitigate risk through patient education, monitoring, and restricted access. However, questions may arise about whether prescribers and patients fully understand the magnitude of risk, especially regarding the interaction of multiple risk factors. For example, a patient who is anti-JCV antibody positive and has been on Tysabri for over two years faces a substantially higher risk, yet the warning may not always be communicated with sufficient clarity about cumulative risk. For affected patients and their families, attorney-related considerations are important. Patients who develop PML after Tysabri treatment may seek legal counsel to explore whether the manufacturer provided adequate warnings about the risk. Key issues include whether the risk of PML was clearly communicated before treatment initiation, whether monitoring protocols were followed, and whether the patient's individual risk factors were properly assessed. The timeline between exposure and documented harm is also critical. PML can develop months to years after starting Tysabri, and symptoms may initially be subtle, leading to delayed diagnosis. The boxed warning instructs healthcare professionals to withhold Tysabri immediately at the first sign or symptom suggestive of PML, but in practice, early symptoms such as cognitive changes or gait disturbance may be mistaken for multiple sclerosis relapse or other conditions. In summary, Tysabri is associated with a well-documented risk of PML, a severe and often fatal brain infection. The FDA has mandated strong warnings and a restricted distribution program, but the adequacy of these measures in practice may be subject to legal scrutiny. Patients who develop PML should be aware of the potential for legal recourse, particularly if they believe they were not adequately informed of the risk or if monitoring was insufficient. The timeline from exposure to harm can be prolonged, and early recognition of PML is critical for any chance of improved outcome.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA requires a boxed warning and a restricted distribution program (TOUCH) due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the main risk factors for developing PML while on Tysabri?

Key risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options do patients have if they develop PML after Tysabri treatment?

Patients may seek legal counsel to evaluate whether the manufacturer provided adequate warnings about PML risks, whether monitoring protocols were followed, and whether individual risk factors were properly assessed. In New Jersey, pharmaceutical liability cases require careful analysis of medical and legal standards.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.